Maximise manufacturing efficiency and scale-ability for miniaturisation and bead milling
/EINPresswire.com/ With 2 months to go join SMi at their 9th annual Controlled Release conference to be held on the 28th & 29th March 2012 London. This must-attend event will once again lead the way in examining the latest developments in nanomedicine and featuring fresh presentations from companies including GlaxoSmithKline, Lundbeck, Merck Serono and Genzyme.
Controlled Release 2012 will allow delegates to meet and network with key decision makers from the top pharmaceutical companies, as well as discuss & debate current issues such as challenges in drug formulation for oral delivery - where are we and what are the prospects for the future, challenges and opportunities for delivering biologics to the CNS and solutions for dissolution testing of non-oral formulations.
Network with key presenters within the pharmaceutical industry that includes:
• Peter Timmins, Executive Director, Drug Products, Science and Technology, Bristol-Myers Squibb
• Mark Wilson, Director, Collaboration Management, GlaxoSmithkline
• Simon Holland, Director, Process Understanding & Control, GlaxoSmithKline
• Bernd Riebesehl, Principal Fellow, Parenteral Dosage Forms, Pharmaceutical and Analytical Development, Novartis
• Mostafa Nakach, Head of the Pharmaceutical Engineering Group, Sanofi-Aventis
• Michael Keller, Senior Fellow, siRNA Project Leader, Technical Research and Development (TRD), Novartis
• Jonathan Brown, Senior Research Investigator, Bristol-Myers Squibb
• Tomas Landh, Director, Novo Nordisk
• Jan L. Powell, Director, Physiology, Shire HGT
• Lars Bauer, Senior Medical Director, Therapeutic Area CNS, UCB
• Karin Liltorp, Director, Preformulation, Lundbeck
Visit www.controlledrelease.co.uk for more information or to register your place. Alternatively, contact Ninica Hussain at Tel: +44 (0) 207 827 6115 or Email: nhussain@smi-online.co.uk
Controlled Release 2012 will allow delegates to meet and network with key decision makers from the top pharmaceutical companies, as well as discuss & debate current issues such as challenges in drug formulation for oral delivery - where are we and what are the prospects for the future, challenges and opportunities for delivering biologics to the CNS and solutions for dissolution testing of non-oral formulations.
Network with key presenters within the pharmaceutical industry that includes:
• Peter Timmins, Executive Director, Drug Products, Science and Technology, Bristol-Myers Squibb
• Mark Wilson, Director, Collaboration Management, GlaxoSmithkline
• Simon Holland, Director, Process Understanding & Control, GlaxoSmithKline
• Bernd Riebesehl, Principal Fellow, Parenteral Dosage Forms, Pharmaceutical and Analytical Development, Novartis
• Mostafa Nakach, Head of the Pharmaceutical Engineering Group, Sanofi-Aventis
• Michael Keller, Senior Fellow, siRNA Project Leader, Technical Research and Development (TRD), Novartis
• Jonathan Brown, Senior Research Investigator, Bristol-Myers Squibb
• Tomas Landh, Director, Novo Nordisk
• Jan L. Powell, Director, Physiology, Shire HGT
• Lars Bauer, Senior Medical Director, Therapeutic Area CNS, UCB
• Karin Liltorp, Director, Preformulation, Lundbeck
Visit www.controlledrelease.co.uk for more information or to register your place. Alternatively, contact Ninica Hussain at Tel: +44 (0) 207 827 6115 or Email: nhussain@smi-online.co.uk
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.